Article ID Journal Published Year Pages File Type
10908985 Leukemia Research 2014 4 Pages PDF
Abstract
For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3 + 7 induction chemotherapy (24 patients). Response rates (P = 0.014) and median overall survival (P = 0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3 + 7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (P = 0.025), respectively. CLAG-M has encouraging activity in this patient group.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , , , , ,